Autogene cevumeran

Phase 2Biologic

Roche

Autogene cevumeran is one of 109 biologic programs targeting Transitional Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transitional Cell CarcinomaRecruiting

MelanomaActive, not recruiting

Adenocarcinoma, Pancreatic DuctalRecruiting

Urothelial CarcinomaActive, not recruiting

Transitional Cell CarcinomaPhase 2

Recruiting

MelanomaPhase 2

Active, not recruiting

Adenocarcinoma, Pancreatic DuctalPhase 2

Recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Leukine

Sanofi

Phase 3

21 2

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

27 3

Libtayo

Regeneron

Phase 3

6 4

Imjudo

AstraZeneca

Phase 3

2 5

Tuoyi

SSun Yat-sen University

Phase 3

4 6

Incomplete Freund's Adjuvant

EEastern Cooperative Oncology Group

Phase 3

20 7

Deltavit

HHyundai Pharmaceutical Co., LTD.

Epacadostat

1 9

Zelboraf

CConrado Roberto Hoffmann Filho

Autogene cevumeran

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Transitional Cell Carcinoma

NCT06534983

Q1 2031

Phase 2Recruiting

Adenocarcinoma, Pancreatic Ductal

NCT05968326

Clinical

Trials by Indication[1]

Melanoma1 trial

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

Completed· Roche logo

Roche·Phase 2·NCT03815058·131 enrolled

Metastatic Tumors1 trial

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT03289962·272 enrolled

Transitional Cell Carcinoma1 trial

A Randomized Phase II, Double-blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-risk Muscle-invasive Urothelial Carcinoma

Recruiting· Roche logo

Roche·Phase 2·NCT06534983·62 enrolled

Adenocarcinoma, Pancreatic Ductal1 trial

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma

Recruiting· Roche logo

Roche·Phase 2·NCT05968326·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Autogene cevumeran. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Autogene cevumeran compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Autogene cevumeran. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Roche

Autogene cevumeran

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2031

Trials by Indication[1]

Melanoma1 trial

Metastatic Tumors1 trial

Transitional Cell Carcinoma1 trial

Adenocarcinoma, Pancreatic Ductal1 trial

References

Drug Info

Quick Facts

Related News